Clovis Oncology Inc is categorized under Commercial Medical Research in Boulder, CO and active since 2009.
Clovis Oncology Inc was established in 2009, and today employs 1 to 4, earning Unknown per year. This is a Commercial Medical Research business, which does work in the B2B market, and is classified as a Commercial Medical Research, under code number 3254120 by the NAICS.
If you are seeking more information, feel free to contact Patrick Mahaffy, Chief Executive Officer at the company’s headquarters by writing to 2525 28th St Unit 100, Boulder, Colorado CO 80301 or by phoning (303) 625-5000. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
Business Name: | Clovis Oncology Inc |
Contact Person: | Patrick Mahaffy, Chief Executive Officer |
Address: | 2525 28th St Unit 100, Boulder, Colorado 80301 |
Phone Number: | (303) 625-5000 |
Website Address: | clovisoncology.com |
Annual Revenue (USD): | Unknown |
Founded: | 2009 |
Location Type: | Headquarters |
Employee Number: | 1 to 4 |
Business Type: | B2B (Business to Business) |
Business Category: | Commercial Medical Research |
SIC Code: | 8731 |
NAICS Code: | 3254120 |
Share This Business: |
Clovis Oncology Inc was started in 2009 to provide professional Commercial Medical Research under the SIC code 8731 and NAICS code 3254120. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of Unknown per annum.
Feel free to contact Patrick Mahaffy, Chief Executive Officer for inquiries that concern Clovis Oncology Inc by calling the company number (303) 625-5000, as your correspondence is most welcome. Additionally, the physical location of the headquarters of Clovis Oncology Inc can be found at the coordinates 40.0263,-105.25844 as well as the street address 2525 28th St Unit 100 in Boulder, Colorado 80301.
For its online presence, you may visit Clovis Oncology Inc’s website at clovisoncology.com and engage with its social media outlets through on Twitter and on Facebook.